Amalia Capilla
Dr. Amalia Capilla is Chief Executive Officer of Miramoon Pharma, with over 15 years of experience in regenerative medicine, gene and cell therapy, and translational research. She holds a PhD in Molecular Biology from the University of Valencia and the Spanish National Research Council and an MBA from EDEM Business School.
Her career spans leadership roles in biotechnology companies and academic institutions, including Director of Project Management at EpiDisease, Head of Operations at Tyris Therapeutics, and Director of Diabetes Cell Therapy at Sigilon Therapeutics (Cambridge, MA), where she advanced pluripotent stem cell–derived pancreatic tissue and biomaterial encapsulation technologies into preclinical development. Dr. Capilla’s postdoctoral research at Boston University and UC San Diego yielded key publications on developmental biology and induced pluripotent stem cell–derived organoids, 3D bioprinting, and wound healing biology.
She has led multidisciplinary teams, coordinated CRO and CMO collaborations, managed clinical operations, and overseen technology transfer processes. Her research has produced over 20 peer-reviewed publications in high-impact journals including Nature Communications, PNAS, and Gut. She is an active mentor in international STEM programs.
